The role of cellular senescence in bone loss and recovery in periodontal disease
细胞衰老在牙周病骨质流失和恢复中的作用
基本信息
- 批准号:10741898
- 负责人:
- 金额:$ 15.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAdverse effectsAgeAge-Related Bone LossAgingAlveolar Bone LossAttenuatedBiologicalBiological AssayBiologyBone ResorptionCell AgingCellsClinical TrialsDevelopmentDiseaseDisease modelExcisionFoundationsFutureGenesGingivaGoalsHumanImmunohistochemistryInduction of ApoptosisInflammationLifeLigatureMandibleMature BoneMeasurementMechanicsMediatorMusMusculoskeletalOsteoclastsOsteogenesisOutcomeOutcome StudyPathologicPathologyPatientsPeriodontal DiseasesPeriodontal LigamentPharmaceutical PreparationsPhenotypePlayPredispositionPrevalencePrevention strategyPublic HealthRecoveryRoleTestingTherapeutic InterventionTissuesTooth CervixTooth LossTooth structureWorkage relatedalternative treatmentalveolar bonebonebone lossclinical efficacyconventional therapyexperimental studyfisetinimprovednovel therapeuticsphenotypic biomarkerpreventsenescencestressortelomeretherapeutically effectivetreatment strategy
项目摘要
Project Summary/Abstract
The prevalence of tooth-supporting alveolar bone loss by periodontal disease (PD) steeply rises in the 3rd
and 4th decades of life. As such, PD is a leading cause of tooth loss in adults. Mechanisms behind the increased
susceptibility to PD bone loss in adulthood are unknown. 17 to 23% of PD patients do not respond to current
treatment and thus progress to tooth loss. Our long-term goal is to identify the mechanism of age-related bone
loss in PD to develop mechanistically based therapies of PD bone loss. A potential factor in the development
of PD bone loss is the accumulation of senescent cells. Senescent cell accumulation in tissues is increasingly
recognized as a driver of age-associated disorders. To mitigate the deleterious effects, senescent cells can be
removed by drugs called senolytics that selectively induce apoptosis in senescent cells. Fisetin is a recently
characterized senolytic without observable adverse effects and is being evaluated in clinical trials targeting
pathological conditions hallmarked by senescent cell burden.
Our preliminary studies using the ligature-induced PD (LIP) model showed that LIP induces initial rapid
bone resorption followed by a rapid recovery due to bone formation by day 14 in young mice (2.5 months). In
contrast, significant bone loss remained at day 14 in mature mice (8-12 months). Also, mature mice showed
greater bone volume loss compared to young mice, indicating the increased susceptibility to LIP-induced bone
loss in mature mice. Furthermore, bone formation rate in mature mice with LIP was lower than young mice,
suggesting that diminished bone formation rate is responsible for the increased susceptibility to LIP-induced
bone loss in mature mice. We found increases in expression levels of senescence marker genes in periodontal
tissue of mature mice before PD induction, suggesting that accumulation of senescent cells in the tissue
increase the susceptibility to LIP-induced bone loss in mature mice. Our hypothesis is that accumulation of
the senescent cells is a critical factor responsible for inhibiting bone recovery and for increasing bone loss
susceptibility in the pathology of PD bone loss, and that senolytic treatment will improves the PD-driven bone
loss. Here, we propose the following aims: Specific Aim 1: Determine if the clearance of pre-existing
senescent cells by the senolytic, fisetin, will prevent PD alveolar bone loss. 12-month-old mice will be pre-
treated with fisetin to clear and prevent age-related senescent accumulation before inducing LIP, and we will
analyze the effect of senescent cell clearance by fisetin pre-treatment on LIP-induced bone loss. Specific Aim
2: Determine if fisetin treatment will induce recovery from PD-induced bone loss. We will induce LIP in 12-
months-old mice and wait until bone resorption progress to detectable levels before starting fisetin treatment.
We will then analyze bone loss induced by LIP. Our team is uniquely suited to conduct these experiments with
expertise in periodontology, bone biology, and cellular senescence in musculoskeletal tissue. Outcomes from
this work will lead us to further mechanistic studies of the role of senescence in PD toward our long-term goal.
项目总结/摘要
牙周病(PD)引起的牙槽骨缺损的患病率在第三年急剧上升,
4th十年的生活因此,PD是成年人牙齿脱落的主要原因。增长背后的机制
成年期PD骨丢失的易感性尚不清楚。17 - 23%的PD患者对当前治疗无反应
治疗,从而导致牙齿脱落。我们的长期目标是确定与年龄相关的骨骼的机制
PD的骨丢失,以开发基于机制的PD骨丢失疗法。发展的一个潜在因素
PD骨丢失的主要原因是衰老细胞的积累。衰老细胞在组织中的积累越来越多
被认为是与年龄相关的疾病的驱动因素。为了减轻有害影响,可以将衰老细胞
被称为senolytics的药物清除,这种药物选择性地诱导衰老细胞的凋亡。非瑟酮是最近
特征性的衰老清除剂没有可观察到的不良反应,正在临床试验中进行评估,
以衰老细胞负荷为特征的病理状况。
我们使用结扎诱导的PD(LIP)模型的初步研究表明,LIP诱导了最初的快速PD,
骨吸收,随后由于在年轻小鼠(2.5个月)中骨形成而在第14天快速恢复。在
相比之下,在成熟小鼠(8 - 12个月)中,在第14天仍然存在显著的骨丢失。此外,成熟的小鼠显示,
与年轻小鼠相比,更大的骨体积损失,表明对LPS诱导的骨的易感性增加
成熟小鼠的损失。此外,LIP成熟小鼠的骨形成率低于年轻小鼠,
这表明骨形成率降低是导致对LPS诱导的骨形成的易感性增加的原因。
成年小鼠的骨丢失。我们发现牙周组织中衰老标记基因的表达水平增加,
在PD诱导前成熟小鼠的组织中,提示衰老细胞在组织中的积累
增加成熟小鼠对脂多糖诱导的骨丢失的易感性。我们的假设是
衰老细胞是负责抑制骨恢复和增加骨损失的关键因素
PD骨丢失的病理学易感性,以及衰老清除治疗将改善PD驱动的骨
损失具体目标1:确定是否清除预先存在的
衰老细胞的senolytic,非瑟酮,将防止PD牙槽骨丢失。12个月大的小鼠将在
在诱导LIP之前用非瑟酮治疗以清除和防止与年龄相关的衰老积累,我们将
分析非瑟酮预处理对衰老细胞的清除作用对脂多糖诱导的骨丢失的影响。具体目标
2:确定非瑟酮治疗是否会诱导PD诱导的骨丢失恢复。我们将在12分钟内诱导LIP-
月大的小鼠,并等待直到骨吸收进展到可检测的水平,然后开始非瑟酮治疗。
然后我们将分析LIP引起的骨丢失。我们的团队非常适合进行这些实验,
牙周病学、骨生物学和肌肉骨骼组织细胞衰老方面的专业知识。的成果
这项工作将引导我们对衰老在PD中的作用进行进一步的机制研究,以实现我们的长期目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mizuho Kittaka其他文献
Mizuho Kittaka的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 15.85万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 15.85万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 15.85万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 15.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 15.85万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 15.85万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)